Serge Monier

Dijon, 21000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity.

High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity.

Journal: Metabolites

Published: January 09, 2023

HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

Journal: Cardiovascular diabetology

Published: June 03, 2022

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 18, 2021

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome.

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome.

Journal: Journal of translational medicine

Published: March 09, 2021

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome.

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome.

Journal: Journal of translational medicine

Published: October 20, 2020

Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate.

Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate.

Journal: Journal of lipid research

Published: April 14, 2017

Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.

Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: October 26, 2016

No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.

No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 20, 2014

Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Journal: Heart and vessels

Published: January 06, 2014

Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation.

Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation.

Journal: Diabetes/metabolism research and reviews

Published: October 08, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026